PDCD1 and cancer: Among them, only 397 patients received the first documented dose of a PD-1 or PD-L1 inhibitor after the diagnosis of cancer; no patients were excluded due to a prior history of severe irHAEs before the first dose of a PD-1 or PD-L1 inhibitor [Figure 1a].